Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers
Inst Canc Res, Div Canc Biol, London, England.;Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA.;Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark..ORCID iD: 0000-0003-4459-7534
Inst Canc Res, Div Canc Biol, London, England.;Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark..
Univ Edinburgh, Ctr Regenerat Med, Edinburgh, Scotland..
Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA.;EydisBio Inc, Durham, NC USA..
Show others and affiliations
2024 (English)In: Cell Death and Disease, E-ISSN 2041-4889, Vol. 15, article id 273Article in journal (Refereed) Published
Abstract [en]

Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and discovered TGFβ activated kinase (TAK1) as a selective survival factor in a significant fraction of GSCs. Loss of TAK1 kinase activity results in RIPK1-dependent apoptosis via Caspase-8/FADD complex activation, dependent on autocrine TNFα ligand production and constitutive TNFR signaling. We identify a transcriptional signature associated with immune activation and the mesenchymal GBM subtype to be a characteristic of cancer cells sensitive to TAK1 perturbation and employ this signature to accurately predict sensitivity to the TAK1 kinase inhibitor HS-276. In addition, exposure to pro-inflammatory cytokines IFN gamma and TNFα can sensitize resistant GSCs to TAK1 inhibition. Our findings reveal dependency on TAK1 kinase activity as a novel vulnerability in immune-activated cancers, including mesenchymal GBMs that can be exploited therapeutically.

Place, publisher, year, edition, pages
Springer Nature, 2024. Vol. 15, article id 273
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-527501DOI: 10.1038/s41419-024-06654-1ISI: 001205160000003PubMedID: 38632238OAI: oai:DiVA.org:uu-527501DiVA, id: diva2:1855867
Funder
EU, Horizon 2020, 749362Available from: 2024-05-03 Created: 2024-05-03 Last updated: 2024-05-03Bibliographically approved

Open Access in DiVA

fulltext(6807 kB)28 downloads
File information
File name FULLTEXT01.pdfFile size 6807 kBChecksum SHA-512
ab375dbc90e83c309bfc49b79f6f9152be6fe8f2436a1fcd440713793548de3d59c2aa4c8d3e71f934afcdc4a3394675685772d591d07a8c49100cc05130fabb
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Uhrbom, Lene

Search in DiVA

By author/editor
Damhofer, HeleneUhrbom, Lene
By organisation
Neurooncology and neurodegeneration
In the same journal
Cell Death and Disease
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 28 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 135 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf